Clinical Trials Logo

Refractory Tumors clinical trials

View clinical trials related to Refractory Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT00856336 Completed - Refractory Tumors Clinical Trials

Phase I Safety Study of DMXAA in Refractory Tumors

DART
Start date: May 2003
Phase: Phase 1
Study type: Interventional

This was a phase I study aimed at identifying safe doses of DMXAA (now known as ASA404) to be used in future combination studies with chemotherapy.

NCT ID: NCT00412503 Completed - Malignant Tumors Clinical Trials

Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents

Start date: n/a
Phase: Phase 1
Study type: Interventional

Long term survival can now be achieved in 75% of cases of pediatric cancers. However, some types of tumors (ie CNS tumors) or advanced stages (metastatic sarcomas/neuroblastomas) cannot be cured by any treatment. Thus, evaluation of new drugs or combinations are strongly needed. The recommended doses have been defined in children for TMZ (200 mg/m2/d x 5 d) and TPT (1.5 mg/m2/d x 5 d). Some preclinical and clinical studies have shown activity of both drugs in some pediatric cancers. Nevertheless, the association of the two drugs has never been evaluated. The study aims to determine Maximum Tolerated Dose and dose limiting toxicities of each drug when associated and to assess efficacy of the combination.